ZebraSci Acquired by BD to Enhance Combination Product Testing Capabilities

August 17, 2021

Overview

Leading global medical technology manufacturer BD has acquired device development, manufacturing, and testing company ZebraSci to enhance drug-device product testing capabilities.

Significance

As injectable delivery methods and drug-device combination products continue to grow in importance, device manufacturers are seeking to expand their capabilities to include testing and validation of these combination products. As one of the largest global medical technology companies in the world, BD is strengthening its leadership position by acquiring these contract development service capabilities. ZebraSci, with its broad suite of manufacturing and testing services for combination products in the injectables market, was the perfect acquisition target for BD.

Crosstree’s Role

Crosstree helped ZebraSci identify the ideal partner to support their growth and expansion goals:

  • Leveraging market expertise to identify a diverse group of potential acquirers
  • Positioning client for maximum value realization
  • Driving an outcome well above our clients’ expectations